Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000255960 | SCV000321996 | pathogenic | not provided | 2022-01-10 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25525159, 20507924, 22135276, 24944099, 30358468, 28559085, 31054281, 31736247, 31047384) |
Labcorp Genetics |
RCV000255960 | SCV001231048 | pathogenic | not provided | 2023-08-29 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg1946*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 265287). This premature translational stop signal has been observed in individuals with Usher syndrome (PMID: 28559085). This variant is present in population databases (rs751130485, gnomAD 0.01%). |
Genome- |
RCV001276244 | SCV004181757 | pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003475859 | SCV004200677 | pathogenic | Retinitis pigmentosa 39 | 2023-12-24 | criteria provided, single submitter | clinical testing | |
Dept Of Ophthalmology, |
RCV003888668 | SCV004707981 | pathogenic | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Natera, |
RCV001276244 | SCV001462251 | pathogenic | Usher syndrome type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |